SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 12.5% - Should You Sell?

Key Points

• SELLAS shares fell 12.5% to about $9.48, with roughly 3.29 million shares traded—61% below average volume. The stock has a $1.95 billion market capitalization and remains well above its 200-day moving average of $6.70.
• Analyst sentiment is mixed: two analysts rate the stock Buy and one rates it Sell, resulting in a consensus Hold rating and an average price target of $10.00.
• SELLAS is a clinical-stage biotechnology company developing cancer immunotherapies targeting the WT1 antigen, led by its investigational multi-peptide vaccine candidate galinpepimut-S (GPS).

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s stock price traded down 12.5% on Tuesday . The company traded as low as $9.44 and last traded at $9.4840. Approximately 3,293,286 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 8,454,730 shares. The stock had previously closed at $10.84.

Analyst Ratings Changes

Several analysts have commented on the stock. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SELLAS Life Sciences Group has an average rating of "Hold" and an average target price of $10.00.

SELLAS Life Sciences Group Stock Down 8.5%

The stock has a market cap of $1.95 billion, a P/E ratio of -43.11 and a beta of 2.42. The business's 50-day simple moving average is $10.43 and its two-hundred day simple moving average is $6.70.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group in the 4th quarter worth about $26,000. BNP Paribas Financial Markets lifted its holdings in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after buying an additional 9,299 shares in the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter valued at approximately $38,000. Beacon Pointe Advisors LLC purchased a new position in SELLAS Life Sciences Group during the fourth quarter valued at approximately $38,000. Finally, California State Teachers Retirement System grew its stake in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after acquiring an additional 1,709 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.